1 |
2023 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2023, 19: 1598-1695.
|
2 |
Jack CR Jr , Bennett DA , Blennow K , Carrillo MC , Dunn B , Haeberlein SB , Holtzman DM , Jagust W , Jessen F , Karlawish J , Liu E , Molinuevo JL , Montine T , Phelps C , Rankin KP , Rowe CC , Scheltens P , Siemers E , Snyder HM , Sperling R , Contributors . NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement, 2018, 14: 535- 562.
doi: 10.1016/j.jalz.2018.02.018
|
3 |
Jack CR Jr , Knopman DS , Jagust WJ , Petersen RC , Weiner MW , Aisen PS , Shaw LM , Vemuri P , Wiste HJ , Weigand SD , Lesnick TG , Pankratz VS , Donohue MC , Trojanowski JQ . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol, 2013, 12: 207- 216.
doi: 10.1016/S1474-4422(12)70291-0
|
4 |
Liu CC , Kanekiyo T , Xu H , Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol, 2013, 9: 106- 118.
doi: 10.1038/nrneurol.2012.263
|
5 |
Chinese Society of Dementia and Cognitive lmpairment , Chinese Society of Nuclear Medicine . Expert consensus on the application of amyloid-PET imaging in the diagnosis of Alzheimer's disease. Zhonghua Yi Xue Za Zhi, 2023, 103: 3615- 3626.
|
|
中华医学会神经病学分会痴呆与认知障碍学组, 中华医学会核医学分会. 淀粉样蛋白PET显像在阿尔茨海默病诊断中的应用专家共识. 中华医学杂志, 2023, 103: 3615- 3626.
|
6 |
Blennow K , de Leon MJ , Zetterberg H . Alzheimer's disease. Lancet, 2006, 368: 387- 403.
doi: 10.1016/S0140-6736(06)69113-7
|
7 |
Farrer LA , Cupples LA , Haines JL , Hyman B , Kukull WA , Mayeux R , Myers RH , Pericak-Vance MA , Risch N , van Duijn CM , APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA, 1997, 278: 1349- 1356.
doi: 10.1001/jama.1997.03550160069041
|
8 |
Kanekiyo T , Xu H , Bu G . ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?. Neuron, 2014, 81: 740- 754.
doi: 10.1016/j.neuron.2014.01.045
|
9 |
Ward A , Crean S , Mercaldi CJ , Collins JM , Boyd D , Cook MN , Arrighi HM . Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology, 2012, 38: 1- 17.
doi: 10.1159/000334607
|
10 |
Corder EH , Saunders AM , Strittmatter WJ , Schmechel DE , Gaskell PC , Small GW , Roses AD , Haines JL , Pericak-Vance MA . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261: 921- 923.
doi: 10.1126/science.8346443
|
11 |
Jia L , Xu H , Chen S , Wang X , Yang J , Gong M , Wei C , Tang Y , Qu Q , Chu L , Shen L , Zhou C , Wang Q , Zhao T , Zhou A , Li Y , Li F , Li Y , Jin H , Qin Q , Jiao H , Li Y , Zhang H , Lyu D , Shi Y , Song Y , Jia J . The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease. Alzheimers Dement, 2020, 16: 1613- 1623.
doi: 10.1002/alz.12153
|
12 |
Feskens EJ , Havekes LM , Kalmijn S , de Knijff P , Launer LJ , Kromhout D . Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ, 1994, 309: 1202- 1206.
doi: 10.1136/bmj.309.6963.1202
|
13 |
Irizarry MC , Rebeck GW , Cheung B , Bales K , Paul SM , Holzman D , Hyman BT . Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann NY Acad Sci, 2000, 920: 171- 178.
doi: 10.1111/j.1749-6632.2000.tb06919.x
|
14 |
Holtzman DM , Bales KR , Tenkova T , Fagan AM , Parsadanian M , Sartorius LJ , Mackey B , Olney J , McKeel D , Wozniak D , Paul SM . Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA, 2000, 97: 2892- 2897.
doi: 10.1073/pnas.050004797
|
15 |
McConnell LM , Sanders GD , Owens DK . Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genet Test, 1999, 3: 47- 53.
doi: 10.1089/gte.1999.3.47
|
16 |
Farrer LA , Brin MF , Elsas L , Goate A , Kennedy J , Mayeux R , Myers RH , Reilly P , Risch NJ . Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA, 1995, 274: 1627- 1629.
doi: 10.1001/jama.1995.03530200063039
|
17 |
Relkin NR , Kwon YJ , Tsai J , Gandy S . The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Ann NY Acad Sci, 1996, 802: 149- 176.
doi: 10.1111/j.1749-6632.1996.tb32608.x
|
18 |
Xiao J , Li J , Wang J , Zhang X , Wang C , Peng G , Hu H , Liu H , Liu J , Shen L , Zhang N , Yan N , Ma Q , Xu W , Liao Z , Ren R , Wang M , Yu E , Tian J , Wang H , Sun Y , Xie H , Wang G . 2023 China Alzheimer's disease: facts and figures. Human Brain, 2023, 2: 1- 13.
|
19 |
Pike KE , Cavuoto MG , Li L , Wright BJ , Kinsella GJ . Subjective cognitive decline: level of risk for future dementia and mild cognitive impairment, a Meta-analysis of longitudinal studies. Neuropsychol Rev, 2022, 32: 703- 735.
doi: 10.1007/s11065-021-09522-3
|
20 |
Reisberg B , Shulman MB , Torossian C , Leng L , Zhu W . Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement, 2010, 6: 11- 24.
doi: 10.1016/j.jalz.2009.10.002
|
21 |
Bennett DA , Wilson RS , Schneider JA , Evans DA , Beckett LA , Aggarwal NT , Barnes LL , Fox JH , Bach J . Natural history of mild cognitive impairment in older persons. Neurology, 2002, 59: 198- 205.
doi: 10.1212/WNL.59.2.198
|
22 |
Chinese Society of Dementia and Cognitive Impairment . Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to Alzheimer's disease 2021. Zhonghua Shen Jing Ke Za Zhi, 2022, 55: 421- 440.
|
|
中华医学会神经病学分会痴呆与认知障碍学组. 阿尔茨海默病源性轻度认知障碍诊疗中国专家共识2021. 中华神经科杂志, 2022, 55: 421- 440.
|
23 |
Müller-Gerards D , Weimar C , Abramowski J , Tebrügge S , Jokisch M , Dragano N , Erbel R , Jöckel KH , Moebus S , Winkler A , Heinz Nixdorf Recall Study Investigative Group . Subjective cognitive decline, APOE ε4, and incident mild cognitive impairment in men and women. Alzheimers Dement (Amst), 2019, 11: 221- 230.
doi: 10.1016/j.dadm.2019.01.007
|
24 |
Samieri C , Proust-Lima C , M Glymour M , Okereke OI , Amariglio RE , Sperling RA , Rentz DM , Grodstein F . Subjective cognitive concerns, episodic memory, and the APOE ε4 allele. Alzheimers Dement, 2014, 10: 752- 759.e1.
doi: 10.1016/j.jalz.2014.06.012
|
25 |
Li JQ , Tan L , Wang HF , Tan MS , Tan L , Xu W , Zhao QF , Wang J , Jiang T , Yu JT . Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry, 2016, 87: 476- 484.
doi: 10.1136/jnnp-2014-310095
|
26 |
Fei M , Jianhua W . Apolipoprotein ε4-allele as a significant risk factor for conversion from mild cognitive impairment to Alzheimer's disease: a meta-analysis of prospective studies. J Mol Neurosci, 2013, 50: 257- 263.
doi: 10.1007/s12031-012-9934-y
|
27 |
Devanand DP , Pelton GH , Zamora D , Liu X , Tabert MH , Goodkind M , Scarmeas N , Braun I , Stern Y , Mayeux R . Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol, 2005, 62: 975- 980.
|
28 |
Hsiung GY , Sadovnick AD , Feldman H . Apolipoprotein E ε4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ, 2004, 171: 863- 867.
doi: 10.1503/cmaj.1031789
|
29 |
Schipper HM . Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention. Alzheimers Dement, 2011, 7: e118- e123.
|
30 |
Hsiung GY , Sadovnick AD . Genetics and dementia: risk factors, diagnosis, and management. Alzheimers Dement, 2007, 3: 418- 427.
doi: 10.1016/j.jalz.2007.07.010
|
31 |
Chinese Expert Consensus Committee on Brain Cognitive Health Management , Chinese Journal of Health Management Editorial Committee . Chinese expert consensus on cognitive health management (2023). Zhonghua Jian Kang Guan Li Xue Za Zhi, 2023, 17: 881- 892.
|
|
脑认知健康管理中国专家共识制定委员会, 《中华健康管理学杂志》编辑委员会. 脑认知健康管理中国专家共识(2023). 中华健康管理学杂志, 2023, 17: 881- 892.
|
32 |
Yu JT , Xu W , Tan CC , Andrieu S , Suckling J , Evangelou E , Pan A , Zhang C , Jia J , Feng L , Kua EH , Wang YJ , Wang HF , Tan MS , Li JQ , Hou XH , Wan Y , Tan L , Mok V , Tan L , Dong Q , Touchon J , Gauthier S , Aisen PS , Vellas B . Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry, 2020, 91: 1201- 1209.
doi: 10.1136/jnnp-2019-321913
|
33 |
Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment Writing Group , Cognitive Disorders Professional Committee, Neurologist Branch, Chinese Medical Doctor Association . Chinese guidelines for primary prevention of Alzheimer's disease. Zhonghua Yi Xue Za Zhi, 2020, 100: 2721- 2735.
URL
|
|
中国痴呆与认知障碍诊治指南写作组, 中国医师协会神经内科医师分会认知障碍疾病专业委员会. 中国阿尔茨海默病一级预防指南. 中华医学杂志, 2020, 100: 2721- 2735.
URL
|
34 |
Wang C , Yu JT , Wang HF , Jiang T , Tan CC , Meng XF , Soares HD , Tan L . Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease. PLoS One, 2014, 9: e89041.
doi: 10.1371/journal.pone.0089041
|
35 |
Rasmussen KL , Tybjaerg-Hansen A , Nordestgaard BG , Frikke-Schmidt R . Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol, 2015, 77: 301- 311.
doi: 10.1002/ana.24326
|
36 |
Wolters FJ , Koudstaal PJ , Hofman A , van Duijn CM , Ikram MA . Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: the Rotterdam Study. Neurosci Lett, 2016, 617: 139- 142.
doi: 10.1016/j.neulet.2016.02.018
|
37 |
Rasmussen KL , Tybjærg-Hansen A , Nordestgaard BG , Frikke-Schmidt R . Plasma apolipoprotein E levels and risk of dementia: a Mendelian randomization study of 106, 562 individuals. Alzheimers Dement, 2018, 14: 71- 80.
doi: 10.1016/j.jalz.2017.05.006
|
38 |
Gupta VB , Laws SM , Villemagne VL , Ames D , Bush AI , Ellis KA , Lui JK , Masters C , Rowe CC , Szoeke C , Taddei K , Martins RN , AIBL Research Group . Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology, 2011, 76: 1091- 1098.
doi: 10.1212/WNL.0b013e318211c352
|
39 |
Giannisis A , Al-Grety A , Carlsson H , Patra K , Twohig D , Sando SB , Lauridsen C , Berge G , Grøntvedt GR , Bråthen G , White LR , Kultima K , Nielsen HM . Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther, 2022, 14: 115.
doi: 10.1186/s13195-022-01058-9
|
40 |
Chao S , Roberts JS , Marteau TM , Silliman R , Cupples LA , Green RC . Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord, 2008, 22: 94- 97.
doi: 10.1097/WAD.0b013e31815a9dcc
|
41 |
Largent EA , Bhardwaj T , Abera M , Stites SD , Harkins K , Lerner AJ , Bradbury AR , Karlawish J . Disclosing genetic risk of Alzheimer's disease to cognitively unimpaired older adults: findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES Ⅱ). J Alzheimers Dis, 2021, 84: 1015- 1028.
doi: 10.3233/JAD-210675
|
42 |
Green RC , Roberts JS , Cupples LA , Relkin NR , Whitehouse PJ , Brown T , Eckert SL , Butson M , Sadovnick AD , Quaid KA , Chen C , Cook-Deegan R , Farrer LA , REVEAL Study Group . Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med, 2009, 361: 245- 254.
doi: 10.1056/NEJMoa0809578
|
43 |
Sng WT , Yeo SN , Lin BX , Lee TS . Impacts of apolipoprotein E disclosure on healthy Asian older adults: a cohort study. Int Psychogeriatr, 2019, 31: 1499- 1507.
doi: 10.1017/S1041610218002089
|
44 |
Alber J , Popescu D , Thompson LI , Tonini GM , Arthur E , Oh H , Correia S , Salloway SP , Lee AK . Safety and tolerability of APOE genotyping and disclosure in cognitively normal volunteers from the Butler Alzheimer's Prevention Registry. J Geriatr Psychiatry Neurol, 2022, 35: 293- 301.
doi: 10.1177/0891988721993575
|
45 |
Lineweaver TT , Bondi MW , Galasko D , Salmon DP . Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry, 2014, 171: 201- 208.
doi: 10.1176/appi.ajp.2013.12121590
|
46 |
Bemelmans SA , Tromp K , Bunnik EM , Milne RJ , Badger S , Brayne C , Schermer MH , Richard E . Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther, 2016, 8: 46.
doi: 10.1186/s13195-016-0212-z
|
47 |
Christensen KD , Karlawish J , Roberts JS , Uhlmann WR , Harkins K , Wood EM , Obisesan TO , Le LQ , Cupples LA , Zoltick ES , Johnson MS , Bradbury MK , Waterston LB , Chen CA , Feldman S , Perry DL , Green RC , REVEAL Study Group . Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment. Alzheimers Dement (NY), 2020, 6: e12002.
doi: 10.1002/trc2.12002
|
48 |
Galluzzi S , Pievani M , Zanetti O , Benussi L , Frisoni GB , Di Maria E , The Italian-DIAfN Working Group . Disclosure of genetic risk factors for Alzheimer's disease to cognitively healthy individuals: from current practice towards a personalised medicine scenario. Biomedicines, 2022, 10: 3177.
doi: 10.3390/biomedicines10123177
|
49 |
Langlois CM , Bradbury A , Wood EM , Roberts JS , Kim SYH , Riviere ME , Liu F , Reiman EM , Tariot PN , Karlawish J , Langbaum JB . Alzheimer's Prevention Initiative Generation Program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (NY), 2019, 5: 705- 716.
doi: 10.1016/j.trci.2019.09.013
|
50 |
Roberts RO , Aakre JA , Kremers WK , Vassilaki M , Knopman DS , Mielke MM , Alhurani R , Geda YE , Machulda MM , Coloma P , Schauble B , Lowe VJ , Jack CR Jr , Petersen RC . Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol, 2018, 75: 970- 979.
doi: 10.1001/jamaneurol.2018.0629
|
51 |
Hatashita S , Wakebe D . Amyloid-β deposition and long-term progression in mild cognitive impairment due to Alzheimer's disease defined with amyloid PET imaging. J Alzheimers Dis, 2017, 57: 765- 773.
doi: 10.3233/JAD-161074
|
52 |
Jansen WJ , Ossenkoppele R , Knol DL , Tijms BM , Scheltens P , Verhey FR , Visser PJ , Aalten P , Aarsland D , Alcolea D , Alexander M , Almdahl IS , Arnold SE , Baldeiras I , Barthel H , van Berckel BN , Bibeau K , Blennow K , Brooks DJ , van Buchem MA , Camus V , Cavedo E , Chen K , Chetelat G , Cohen AD , Drzezga A , Engelborghs S , Fagan AM , Fladby T , Fleisher AS , van der Flier WM , Ford L , Förster S , Fortea J , Foskett N , Frederiksen KS , Freund-Levi Y , Frisoni GB , Froelich L , Gabryelewicz T , Gill KD , Gkatzima O , Gómez-Tortosa E , Gordon MF , Grimmer T , Hampel H , Hausner L , Hellwig S , Herukka SK , Hildebrandt H , Ishihara L , Ivanoiu A , Jagust WJ , Johannsen P , Kandimalla R , Kapaki E , Klimkowicz-Mrowiec A , Klunk WE , Köhler S , Koglin N , Kornhuber J , Kramberger MG , Van Laere K , Landau SM , Lee DY , de Leon M , Lisetti V , Lleó A , Madsen K , Maier W , Marcusson J , Mattsson N , de Mendonça A , Meulenbroek O , Meyer PT , Mintun MA , Mok V , Molinuevo JL , Møllergård HM , Morris JC , Mroczko B , Van der Mussele S , Na DL , Newberg A , Nordberg A , Nordlund A , Novak GP , Paraskevas GP , Parnetti L , Perera G , Peters O , Popp J , Prabhakar S , Rabinovici GD , Ramakers IH , Rami L , Resende de Oliveira C , Rinne JO , Rodrigue KM , Rodríguez-Rodríguez E , Roe CM , Rot U , Rowe CC , Rüther E , Sabri O , Sanchez-Juan P , Santana I , Sarazin M , Schröder J , Schütte C , Seo SW , Soetewey F , Soininen H , Spiru L , Struyfs H , Teunissen CE , Tsolaki M , Vandenberghe R , Verbeek MM , Villemagne VL , Vos SJ , van Waalwijk van Doorn LJ , Waldemar G , Wallin A , Wallin ÅK , Wiltfang J , Wolk DA , Zboch M , Zetterberg H , Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA, 2015, 313: 1924- 1938.
doi: 10.1001/jama.2015.4668
|
53 |
Liu Y , Yu JT , Wang HF , Han PR , Tan CC , Wang C , Meng XF , Risacher SL , Saykin AJ , Tan L . APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry, 2015, 86: 127- 134.
doi: 10.1136/jnnp-2014-307719
|
54 |
Ossenkoppele R , Jansen WJ , Rabinovici GD , Knol DL , van der Flier WM , van Berckel BN , Scheltens P , Visser PJ , Amyloid PET Study Group , Verfaillie SC , Zwan MD , Adriaanse SM , Lammertsma AA , Barkhof F , Jagust WJ , Miller BL , Rosen HJ , Landau SM , Villemagne VL , Rowe CC , Lee DY , Na DL , Seo SW , Sarazin M , Roe CM , Sabri O , Barthel H , Koglin N , Hodges J , Leyton CE , Vandenberghe R , van Laere K , Drzezga A , Forster S , Grimmer T , Sánchez-Juan P , Carril JM , Mok V , Camus V , Klunk WE , Cohen AD , Meyer PT , Hellwig S , Newberg A , Frederiksen KS , Fleisher AS , Mintun MA , Wolk DA , Nordberg A , Rinne JO , Chételat G , Lleo A , Blesa R , Fortea J , Madsen K , Rodrigue KM , Brooks DJ . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA, 2015, 313: 1939- 1949.
doi: 10.1001/jama.2015.4669
|
55 |
Ba M , Kong M , Li X , Ng KP , Rosa-Neto P , Gauthier S . Is ApoE ε 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?. Transl Neurodegener, 2016, 5: 20.
doi: 10.1186/s40035-016-0067-z
|
56 |
Ba M , Ng KP , Gao X , Kong M , Guan L , Yu L , Alzheimer's Disease Neuroimaging Initiative . The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale: Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Eur J Neurol, 2019, 26: 733- e53.
doi: 10.1111/ene.13881
|
57 |
Ten Kate M , Redolfi A , Peira E , Bos I , Vos SJ , Vandenberghe R , Gabel S , Schaeverbeke J , Scheltens P , Blin O , Richardson JC , Bordet R , Wallin A , Eckerstrom C , Molinuevo JL , Engelborghs S , Van Broeckhoven C , Martinez-Lage P , Popp J , Tsolaki M , Verhey FRJ , Baird AL , Legido-Quigley C , Bertram L , Dobricic V , Zetterberg H , Lovestone S , Streffer J , Bianchetti S , Novak GP , Revillard J , Gordon MF , Xie Z , Wottschel V , Frisoni G , Visser PJ , Barkhof F . MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers Res Ther, 2018, 10: 100.
doi: 10.1186/s13195-018-0428-1
|
58 |
Shan G , Bernick C , Caldwell JZK , Ritter A . Machine learning methods to predict amyloid positivity using domain scores from cognitive tests. Sci Rep, 2021, 11: 4822.
doi: 10.1038/s41598-021-83911-9
|
59 |
Ashford MT , Veitch DP , Neuhaus J , Nosheny RL , Tosun D , Weiner MW . The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: a systematic review of the prediction of brain amyloid status. Alzheimers Dement, 2021, 17: 866- 887.
doi: 10.1002/alz.12253
|
60 |
Mielke MM , Wiste HJ , Weigand SD , Knopman DS , Lowe VJ , Roberts RO , Geda YE , Swenson-Dravis DM , Boeve BF , Senjem ML , Vemuri P , Petersen RC , Jack CR Jr . Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 2012, 79: 1570- 1577.
doi: 10.1212/WNL.0b013e31826e2696
|
61 |
Langford O , Raman R , Sperling RA , Cummings J , Sun CK , Jimenez-Maggiora G , Aisen PS , Donohue MC . Predicting amyloid burden to accelerate recruitment of secondary prevention clinical trials. J Prev Alzheimers Dis, 2020, 7: 213- 218.
|
62 |
Zhang J , Zhou W , Cassidy RM , Su H , Su Y , Zhang X , Alzheimer's Disease Neuroimaging Initiative . Risk factors for amyloid positivity in older people reporting significant memory concern. Compr Psychiatry, 2018, 80: 126- 131.
doi: 10.1016/j.comppsych.2017.09.015
|
63 |
Janssen O , Jansen WJ , Vos SJB , Boada M , Parnetti L , Gabryelewicz T , Fladby T , Molinuevo JL , Villeneuve S , Hort J , Epelbaum S , Lleó A , Engelborghs S , van der Flier WM , Landau S , Popp J , Wallin A , Scheltens P , Rikkert MO , Snyder PJ , Rowe C , Chételat G , Ruíz A , Marquié M , Chipi E , Wolfsgruber S , Heneka M , Boecker H , Peters O , Jarholm J , Rami L , Tort-Merino A , Binette AP , Poirier J , Rosa-Neto P , Cerman J , Dubois B , Teichmann M , Alcolea D , Fortea J , Sánchez-Saudinós MB , Ebenau J , Pocnet C , Eckerström M , Thompson L , Villemagne V , Buckley R , Burnham S , Delarue M , Freund-Levi Y , Wallin ÅK , Ramakers I , Tsolaki M , Soininen H , Hampel H , Spiru L , Tijms B , Ossenkoppele R , Verhey FRJ , Jessen F , Visser PJ , Alzheimer's Disease Neuroimaging Initiative , FACEHBI Study Group , PREVENT-AD Research Group . Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement, 2022, 18: 1832- 1845.
doi: 10.1002/alz.12512
|
64 |
Karikari TK , Ashton NJ , Brinkmalm G , Brum WS , Benedet AL , Montoliu-Gaya L , Lantero-Rodriguez J , Pascoal TA , Suárez-Calvet M , Rosa-Neto P , Blennow K , Zetterberg H . Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol, 2022, 18: 400- 418.
doi: 10.1038/s41582-022-00665-2
|
65 |
Karikari TK , Benedet AL , Ashton NJ , Lantero Rodriguez J , Snellman A , Suárez-Calvet M , Saha-Chaudhuri P , Lussier F , Kvartsberg H , Rial AM , Pascoal TA , Andreasson U , Schöll M , Weiner MW , Rosa-Neto P , Trojanowski JQ , Shaw LM , Blennow K , Zetterberg H , Alzheimer's Disease Neuroimaging Initiative . Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry, 2021, 26: 429- 442.
doi: 10.1038/s41380-020-00923-z
|
66 |
Pereira JB , Janelidze S , Smith R , Mattsson-Carlgren N , Palmqvist S , Teunissen CE , Zetterberg H , Stomrud E , Ashton NJ , Blennow K , Hansson O . Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain, 2021, 144: 3505- 3516.
doi: 10.1093/brain/awab223
|
67 |
Yang Z , Sreenivasan K , Toledano Strom EN , Osse AML , Pasia LG , Cosme CG , Mugosa MRN , Chevalier EL , Ritter A , Miller JB , Cordes D , Cummings JL , Kinney JW . Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease. Alzheimers Res Ther, 2023, 15: 190.
doi: 10.1186/s13195-023-01340-4
|
68 |
Cheng L , Li W , Chen Y , Lin Y , Wang B , Guo Q , Miao Y . Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease: a systematic review with meta-analysis. J Neurol Neurosurg Psychiatry, 2022, 93: 513- 520.
doi: 10.1136/jnnp-2021-327864
|
69 |
Martínez-Dubarbie F , Guerra-Ruiz A , López-García S , Lage C , Fernández-Matarrubia M , Infante J , Pozueta-Cantudo A , García-Martínez M , Corrales-Pardo A , Bravo M , López-Hoyos M , Irure-Ventura J , Sánchez-Juan P , García-Unzueta MT , Rodríguez-Rodríguez E . Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimers Res Ther, 2023, 15: 163.
doi: 10.1186/s13195-023-01319-1
|
70 |
West T , Kirmess KM , Meyer MR , Holubasch MS , Knapik SS , Hu Y , Contois JH , Jackson EN , Harpstrite SE , Bateman RJ , Holtzman DM , Verghese PB , Fogelman I , Braunstein JB , Yarasheski KE . A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener, 2021, 16: 30.
doi: 10.1186/s13024-021-00451-6
|
71 |
Udeh-Momoh C , Zheng B , Sandebring-Matton A , Novak G , Kivipelto M , Jönsson L , Middleton L . Blood derived amyloid biomarkers for Alzheimer's disease prevention. J Prev Alzheimers Dis, 2022, 9: 12- 21.
|
72 |
Ngandu T , Lehtisalo J , Solomon A , Levälahti E , Ahtiluoto S , Antikainen R , Bäckman L , Hänninen T , Jula A , Laatikainen T , Lindström J , Mangialasche F , Paajanen T , Pajala S , Peltonen M , Rauramaa R , Stigsdotter-Neely A , Strandberg T , Tuomilehto J , Soininen H , Kivipelto M . A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet, 2015, 385: 2255- 2263.
doi: 10.1016/S0140-6736(15)60461-5
|
73 |
Kivipelto M , Mangialasche F , Ngandu T . Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol, 2018, 14: 653- 666.
doi: 10.1038/s41582-018-0070-3
|
74 |
Lourida I , Hannon E , Littlejohns TJ , Langa KM , Hyppönen E , Kuzma E , Llewellyn DJ . Association of lifestyle and genetic risk with incidence of dementia. JAMA, 2019, 322: 430- 437.
doi: 10.1001/jama.2019.9879
|
75 |
Licher S , Ahmad S , Karamujić-Čomić H , Voortman T , Leening MJG , Ikram MA , Ikram MK . Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. Nat Med, 2019, 25: 1364- 1369.
doi: 10.1038/s41591-019-0547-7
|
76 |
Solomon A , Turunen H , Ngandu T , Peltonen M , Levälahti E , Helisalmi S , Antikainen R , Bäckman L , Hänninen T , Jula A , Laatikainen T , Lehtisalo J , Lindström J , Paajanen T , Pajala S , Stigsdotter-Neely A , Strandberg T , Tuomilehto J , Soininen H , Kivipelto M . Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol, 2018, 75: 462- 470.
doi: 10.1001/jamaneurol.2017.4365
|
77 |
Jia J , Zhao T , Liu Z , Liang Y , Li F , Li Y , Liu W , Li F , Shi S , Zhou C , Yang H , Liao Z , Li Y , Zhao H , Zhang J , Zhang K , Kan M , Yang S , Li H , Liu Z , Ma R , Lv J , Wang Y , Yan X , Liang F , Yuan X , Zhang J , Gauthier S , Cummings J . Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study. BMJ, 2023, 380: e072691.
|
78 |
Dhana K , Aggarwal NT , Rajan KB , Barnes LL , Evans DA , Morris MC . Impact of the apolipoprotein E ε4 allele on the relationship between healthy lifestyle and cognitive decline: a population-based study. Am J Epidemiol, 2021, 190: 1225- 1233.
doi: 10.1093/aje/kwab033
|
79 |
Dhana K , Barnes LL , Liu X , Agarwal P , Desai P , Krueger KR , Holland TM , Halloway S , Aggarwal NT , Evans DA , Rajan KB . Genetic risk, adherence to a healthy lifestyle, and cognitive decline in African Americans and European Americans. Alzheimers Dement, 2022, 18: 572- 580.
doi: 10.1002/alz.12435
|